Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,609.78
(
0.13%
)
US TECH 100
29,850.80
(
0.01%
)
Dow Jones
51,307.79
(
0.45%
)
Brent Oil
96.86
(
1.68%
)
Bitcoin
67,065.99
(
0.57%
)
News Focus
News Focus
Post# of 257692
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123058
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 216234

Wednesday, 12/27/2017 1:42:12 PM

Wednesday, December 27, 2017 1:42:12 PM

Post# of 257692
(ADXS)—75% of hypermutated CRC cases have MSI-high (according to the article you posted), but MSI-high CRC is excluded from the (planned) phase-1 trials of ADXS-NEO:

https://ir.advaxis.com/press-releases/detail/1280/advaxis-reports-business-update-and-third-quarter-2017

The initial tumor types for ADXS-NEO are metastatic microsatellite stable colon, head and neck, and non-small cell lung cancers.

Emphasis added.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today